Evidence map›Paper›PMID 40895577›Full record

ArticleFrontiers in immunology2025

PD-1 and LAG-3 were optimal combination of immune checkpoints for predicting poor clinical outcomes of patients with ovarian cancer.

Yifan Wu, Cunte Chen, Yingwen Cui, Ruoyao Zou, Yaoxiang Yang, Fengjie Sun, Yanzi Du, Peipei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yifan Wu *Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Cunte Chen *Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Yingwen Cui *Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Ruoyao ZouGuangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Yaoxiang YangGuangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Fengjie SunDepartment of Neonatology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yanzi DuCenter for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Peipei WangGuangzhou First People's Hospital, South China University of Technology, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although immune checkpoint blockade (ICB) therapy has transformed the therapeutic landscape for ovarian cancer (OC), the predictive utility of immune checkpoint (IC) expression signatures in stratifying clinical outcomes requires further systematic interrogation. Methods: Transcriptomic profiles from 147 OC patients within The Cancer Genome Atlas (TCGA) cohort were interrogated to assess the prognostic significance of ICs. These genomic findings were subsequently validated through immunohistochemical analysis of an independent institutional cohort comprising 74 OC tissue specimens. Results: Both TCGA and validation cohorts demonstrated that elevated expression of PD-1 and LAG-3 correlated with inferior overall survival (OS) in patients with OC. Importantly, among the ICs, PD-1/LAG-3 co-expression emerged as the optimal combinatorial biomarker, independently predicting adverse outcomes [hazard ratio (HR) = 1.74, 95% confidence interval (CI): 1.12-2.70, Conclusion: Elevated IC expression correlated with poor OS in OC patients. Specifically, PD-1/LAG-3 co-expression emerged as the optimal prognostic biomarker pair, representing a promising therapeutic target for dual checkpoint blockade strategies in OC.

Indexed as

Antigens, CDBiomarkers, TumorOvarian NeoplasmsProgrammed Cell Death 1 ReceptorAdultAgedFemaleGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinMiddle AgedNomogramsPrognosisAntigens, CDBiomarkers, TumorImmune Checkpoint InhibitorsLag3 protein, humanLymphocyte Activation Gene 3 ProteinPDCD1 protein, humanProgrammed Cell Death 1 Receptorimmune checkpointLAG-3ovarian cancerPD-1prognosis

Identifiers

PMID40895577
PMCPMC12390975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.